A broad range of translational cancer research is conducted in this area, particularly in sarcomas, head-and-neck, breast, ovarian, endometrial, colorectal and haematological cancers, among others. Research covers a wide range of fields, with disciplines that include from genetic research on cancer susceptibility syndromes to advanced therapies such as those based on targeted drug delivery with nanoparticles, preclinical development of new anticancer agents with disease-specific mouse models, immunotherapy with CAR-T cells, gene therapy, drug repurposing and predictive molecular markers. Next generation sequencing approaches are developed and applied to identify novel prognostic or response factors. A large number of clinical trials are performed within this area by our clinical researchers, including phase I, II and III trials with new anticancer drugs.
